Abstract
Alzheimer’s disease (AD) is contributed by multiple pathogenic causes. The anomalous protein amyloid-β (Aβ) is regarded as a pivotal factor in AD, and originates from enzymatic cleavage of a precursor protein by the secretase family. 1-(3’,4’-Dichloro-2-fluoro[1,1’-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074) is a non-steroidal antiinflammatory derivative able to inhibit Aβ deposition in the brain of transgenic mouse models of AD. The proapoptotic cytokine TRAIL has been reported to mediate Aβ-dependent neurotoxicity. Here, the effects of CHF5074 on Aβ25-35- triggered TRAIL toxicity were evaluated in the differentiated human neuroblastoma cell line SH-SY5Y in vitro. Cells were pre-treated 1h with CHF5074 at graded concentrations (range: 1 nM-1uM) and then challenged for 72 h with either Aβ25-35 or TRAIL. Results show that CHF5074 treatment prevented apoptotic death in SH-SY5Y cell line in a concentration- dependent fashion. Its maximally active concentration was 10 nM. Then, investigation of related molecular mechanisms underlying such protective effect of CHF5074 suggested that the levels of caspases, as well as of various kinases, including stress and MAP kinases, are modulated by CHF5074. Finally, treatment of injured human neuroblastoma cell line SH-SY5Y with CHF5074 resulted in prominent protection from apoptotic death. The bulk of these data suggest that CHF5074 represents a potential candidate for pharmacological neuroprotective treatment in neurodegenerative disorders.
Keywords: Alzheimer's disease, neuroinflammation, proapoptotic cytokines, treatment.
Current Alzheimer Research
Title:CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Volume: 11 Issue: 7
Author(s): Nicole Ronsisvalle, Giulia Di Benedetto, Carmela Parenti, Salvatore Amoroso, Renato Bernardini and Giuseppina Cantarella
Affiliation:
Keywords: Alzheimer's disease, neuroinflammation, proapoptotic cytokines, treatment.
Abstract: Alzheimer’s disease (AD) is contributed by multiple pathogenic causes. The anomalous protein amyloid-β (Aβ) is regarded as a pivotal factor in AD, and originates from enzymatic cleavage of a precursor protein by the secretase family. 1-(3’,4’-Dichloro-2-fluoro[1,1’-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074) is a non-steroidal antiinflammatory derivative able to inhibit Aβ deposition in the brain of transgenic mouse models of AD. The proapoptotic cytokine TRAIL has been reported to mediate Aβ-dependent neurotoxicity. Here, the effects of CHF5074 on Aβ25-35- triggered TRAIL toxicity were evaluated in the differentiated human neuroblastoma cell line SH-SY5Y in vitro. Cells were pre-treated 1h with CHF5074 at graded concentrations (range: 1 nM-1uM) and then challenged for 72 h with either Aβ25-35 or TRAIL. Results show that CHF5074 treatment prevented apoptotic death in SH-SY5Y cell line in a concentration- dependent fashion. Its maximally active concentration was 10 nM. Then, investigation of related molecular mechanisms underlying such protective effect of CHF5074 suggested that the levels of caspases, as well as of various kinases, including stress and MAP kinases, are modulated by CHF5074. Finally, treatment of injured human neuroblastoma cell line SH-SY5Y with CHF5074 resulted in prominent protection from apoptotic death. The bulk of these data suggest that CHF5074 represents a potential candidate for pharmacological neuroprotective treatment in neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Ronsisvalle Nicole, Benedetto Di Giulia, Parenti Carmela, Amoroso Salvatore, Bernardini Renato and Cantarella Giuseppina, CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro, Current Alzheimer Research 2014; 11 (7) . https://dx.doi.org/10.2174/1567205011666140618104430
DOI https://dx.doi.org/10.2174/1567205011666140618104430 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Current Pharmaceutical Design Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Neuroprotective Effect of Dexmedetomidine Pretreatment on Sevoflurane- Initiated Neurotoxicity <i>Via</i> the Mir-204-5p/SOX4 Axis
Protein & Peptide Letters ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Implication of Complement System and its Regulators in Alzheimers Disease
Current Neuropharmacology Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Listeria monocytogenes as a Vector for Anti-Cancer Therapies
Current Gene Therapy Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry Mangiferin – a Bioactive Xanthonoid, not only from Mango and not just Antioxidant
Mini-Reviews in Medicinal Chemistry The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience
Reviews on Recent Clinical Trials Metallothioneins and Cancer
Current Protein & Peptide Science